Piramal Pharma Limited announced its unaudited standalone and consolidated financial results for the quarter ended 30th June, 2026, during the Board of Directors meeting held on 29th July, 2026. On a consolidated basis, the company reported revenue from operations of Rs. 2,269.92 Crores, reflecting an increase compared to the corresponding quarter last year, though net results reflected a net loss after tax of Rs. 69.39 Crores. A comparative overview of the consolidated financial results highlights a revenue decrease of 17.51% sequentially (QoQ) against Rs. 2,751.77 Crores, and a revenue increase of 17.39% year-over-year (YoY) compared to Rs. 1,933.71 Crores. Net profit after tax showed a reduced loss compared to a loss of Rs. 8,170 Lakhs (Rs. 81.70 Crores) in the corresponding quarter last year, achieving a 15.07% improvement in loss terms.

Piramal Pharma Limited is a leading global pharmaceutical company operating across key business segments including Contract Development and Manufacturing Organization (CDMO), Complex Hospital Generics (CHG), and India Consumer Healthcare (ICH). The company boasts a robust quality track record, maintaining a zero-OAI status across multiple regulatory inspections. Recent updates indicate expanding capacities and strong order inflows across international and domestic sites. Famous institutional investors in the company include CA Alchemy Investments (an affiliate of The Carlyle Group), which holds a significant stake alongside the promoter group led by Ajay Piramal and family.